Cargando…

Spinal meningiomas

Spinal meningiomas (SM) are lesions with a mostly favorable oncological and surgical prognosis and a low incidence of tumor recurrence. SM account for approximately 1.2–12.7% of all meningiomas and 25% of all spinal cord tumors. Typically, SM are located in the intradural extramedullary space. SM gr...

Descripción completa

Detalles Bibliográficos
Autores principales: Hohenberger, Christoph, Hau, Peter, Schebesch, Karl-Michael, Kölbl, Oliver, Riemenschneider, Markus J, Pohl, Fabian, Proeschold, Martin, Schmidt, Nils Ole
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243846/
https://www.ncbi.nlm.nih.gov/pubmed/37287574
http://dx.doi.org/10.1093/noajnl/vdad013
_version_ 1785054512026746880
author Hohenberger, Christoph
Hau, Peter
Schebesch, Karl-Michael
Kölbl, Oliver
Riemenschneider, Markus J
Pohl, Fabian
Proeschold, Martin
Schmidt, Nils Ole
author_facet Hohenberger, Christoph
Hau, Peter
Schebesch, Karl-Michael
Kölbl, Oliver
Riemenschneider, Markus J
Pohl, Fabian
Proeschold, Martin
Schmidt, Nils Ole
author_sort Hohenberger, Christoph
collection PubMed
description Spinal meningiomas (SM) are lesions with a mostly favorable oncological and surgical prognosis and a low incidence of tumor recurrence. SM account for approximately 1.2–12.7% of all meningiomas and 25% of all spinal cord tumors. Typically, SM are located in the intradural extramedullary space. SM grow slowly and spread laterally into the subarachnoid space, stretching and sometimes incorporating the surrounding arachnoid but rarely the pia. Standard treatment is surgery with the primary aims of achieving complete tumor resection as well as improving and recovering neurologic function. Radiotherapy may be considered in case of tumor recurrence, for challenging surgical cases, and for patients with higher-grade lesions (World Health Organization grade 2 or 3); however, radiotherapy is mostly used as an adjuvant therapy for SM. New molecular and genetic profiling increases the understanding of SM and may uncover additional treatment options.
format Online
Article
Text
id pubmed-10243846
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-102438462023-06-07 Spinal meningiomas Hohenberger, Christoph Hau, Peter Schebesch, Karl-Michael Kölbl, Oliver Riemenschneider, Markus J Pohl, Fabian Proeschold, Martin Schmidt, Nils Ole Neurooncol Adv Supplement Articles Spinal meningiomas (SM) are lesions with a mostly favorable oncological and surgical prognosis and a low incidence of tumor recurrence. SM account for approximately 1.2–12.7% of all meningiomas and 25% of all spinal cord tumors. Typically, SM are located in the intradural extramedullary space. SM grow slowly and spread laterally into the subarachnoid space, stretching and sometimes incorporating the surrounding arachnoid but rarely the pia. Standard treatment is surgery with the primary aims of achieving complete tumor resection as well as improving and recovering neurologic function. Radiotherapy may be considered in case of tumor recurrence, for challenging surgical cases, and for patients with higher-grade lesions (World Health Organization grade 2 or 3); however, radiotherapy is mostly used as an adjuvant therapy for SM. New molecular and genetic profiling increases the understanding of SM and may uncover additional treatment options. Oxford University Press 2023-06-03 /pmc/articles/PMC10243846/ /pubmed/37287574 http://dx.doi.org/10.1093/noajnl/vdad013 Text en © The Author(s) 2023. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Supplement Articles
Hohenberger, Christoph
Hau, Peter
Schebesch, Karl-Michael
Kölbl, Oliver
Riemenschneider, Markus J
Pohl, Fabian
Proeschold, Martin
Schmidt, Nils Ole
Spinal meningiomas
title Spinal meningiomas
title_full Spinal meningiomas
title_fullStr Spinal meningiomas
title_full_unstemmed Spinal meningiomas
title_short Spinal meningiomas
title_sort spinal meningiomas
topic Supplement Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243846/
https://www.ncbi.nlm.nih.gov/pubmed/37287574
http://dx.doi.org/10.1093/noajnl/vdad013
work_keys_str_mv AT hohenbergerchristoph spinalmeningiomas
AT haupeter spinalmeningiomas
AT schebeschkarlmichael spinalmeningiomas
AT kolbloliver spinalmeningiomas
AT riemenschneidermarkusj spinalmeningiomas
AT pohlfabian spinalmeningiomas
AT proescholdmartin spinalmeningiomas
AT schmidtnilsole spinalmeningiomas